Read the latest articles covering Southeastern, Longleaf and our team in various periodicals and publications.
Staley Cates and Ross Glotzbach discuss the decision to reopen the Longleaf Partners Small-Cap Fund and share their views on opportunities that have arisen amid the coronavirus crisis and their long-term outlook for the small-cap space.
The listed articles have appeared in various periodicals and publications over time and are not a complete list of writings about Southeastern or Longleaf. The publications control the timing and content, which has not been updated since the dates shown. The statements and opinions expressed are those of the author and are as of the date of the interview or article. Southeastern’s views may have changed, and the articles are not a recommendation to buy any security. It should not be assumed that an investment in the securities mentioned was or would be profitable in the future. Top 10 holdings for each Fund, as of the most recent quarter end, can be found at the following links.
These articles must be preceded or accompanied by a current Longleaf Prospectus. View performance information and the Prospectus and Summary Prospectus, which should be read carefully before investing to learn about the investment objectives, risks, charges and expenses of the Longleaf Partners Funds. Past performance does not guarantee future results. Please click here for definitions of certain terms used.
Longleaf Partners Funds are distributed by ALPS Distributors, Inc. There is no affiliation between Southeastern Asset Management and ALPS.
For those interested in the Longleaf Partners UCITS Funds, the articles tend to concern the US Longleaf Funds, not the UCITS Funds. For more information on the UCITS Funds, including a prospectus and Key Investor Information Document (KIID), potential eligible investors should call +44 (0) 20 7479 4200 or [email protected]. Potential eligible investors should read the prospectus and Key Investor Information Document (KIID) carefully, considering the investment objectives, risks, charges, and expenses of the product, before making any investment decision.